The present invention provides methods of attenuating or preventing brain injury mediated damage in the central nervous system by attenuating or preventing leukotriene-rnediated events following a brain injury or long-term neuroinflammation after brain injury, in Alzheimers disease, multiple sclerosis, stroke, and post-traumatic stress disorder. The methods comprise administering at least one 5-lipoxygenase activating protein (FLAP) inhibitor either before or after the brain Injury. The method finds use in the treatment of traumatic brain injury (TBI), stroke, multiple sclerosis, Alzheimers disease, post-traumatic stress disorder and other brain injuries associated with production of leukotrienes in the central nervous system. Preferably die FLAP inhibitor is administered intranasally and preferably for certain high risk individuals prophylactically prior to any potential brain injury event.
